Skip to main content

Table 3 Comparison of transarterial chemoembolization with radiofrequency ablation versus transarterial chemoembolization of patients with BCLC stage B hepatocellular carcinoma after propensity score matching

From: Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis

VariableTACE+RFA (n = 56)TACE (n = 231)P-value
Male42 (75.0)173 (74.9)0.987
Age (years)64 (28–86)64 (29–91)0.672
Smoking27 (47.4)113 (48.9)0.925
Alcohol use23 (40.4)100 (43.3)0.763
HBV positive32 (56.1)103 (44.6)0.091
HCV positive21 (36.8)90 (39.0)0.085
Total Bilirubin1.41 ± 0.671.34 ± 1.140.643
INR1.10 ± 0.141.06 ± 0.120.060
Cirrhosis43 (75.4)155 (67.1)0.160
Child-Pugh class A43 (76.8)194 (84.0)0.203
Tumor size5.5 ± 2.67.0 ± 3.80.062
Tumor size≥5 cm25 (44.6)149 (64.5)0.053
Tumor number (≥3)50 (89.3)178 (77.1)0.051
AFP (ng/mL) ≥ 2006 (10.7)50 (21.6)0.064
Mortality34 (59.6)173 (74..9)0.034
Follow up times (months)36 (3–95)22 (1–97)< 0.0001
  1. BCLC stage: Barcelona clinic liver cancer; SR Surgical resection; TACE Transcatheter arterial chemoembolization; RFA Radiofrequency ablation; HBV Hepatitis B virus; HCV Hepatitis C virus; AFP: INR International normalize ratio; Alpha-fetoprotein;